Comparison of serum prostate specific membrane antigen, prostate specific antigen, and free prostate specific antigen levels in radical prostatectomy patients

Cancer

Volumn 80, Issue 1, 1997, Pages 107-114

  Douglas, Thomas H ^a,b   Morgan, Ted O ^a,b   McLeod, David G ^a,b   Moul, Judd W ^a,b   Murphy, Gerald P ^c   Barren III, Robert ^c   Sesterhenn, Isabell A ^b,d   Mostofi, Fathollah K ^b,d  

^a WALTER REED ARMY MEDICAL CENTER   (United States)

^b UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^c PACIFIC NORTHWEST RESEARCH INSTITUTE   (United States)

^d ARMED FORCES INSTITUTE OF PATHOLOGY   (United States)

Author keywords

Free prostate specific antigen; Prostate carcinoma; Prostate specific antigen; Prostate specific membrane antigen; Radical prostatectomy

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; DIAGNOSTIC ACCURACY; DISEASE ASSOCIATION; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; TUMOR VOLUME;

AGED; ANTIGENS, NEOPLASM; ANTIGENS, SURFACE; GLUTAMATE CARBOXYPEPTIDASE II; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; ROC CURVE;

EID: 0030926498     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19970701)80:1<107::AID-CNCR14>3.0.CO;2-1     Document Type: Article

References (29)

1. Mettlin C, Littrup PJ, Kane RA, Murphy GP, Lee F, Chesley A, et al. For the investigators of the American Cancer Society National Prostate Cancer Detection Project. Relative sensitivity and specificity of serum prostate specific antigen (PSA) level compared with age-referenced PSA, PSA density and PSA change: data from the American Cancer Society National Prostate Cancer Detection Project. Cancer 1994;74:1615-20.
2. Babaian RJ, Mettlin C, Kane R, Murphy GP, Lee F, Drago JR, et al. and the Investigators of the American Cancer Society National Prostate Cancer Detection Project. The relationship of prostate-specific antigen to digital rectal examination and transrectal ultrasonography: findings of the American Cancer Society-National Prostate Cancer Detection Project. Cancer 1992;69:1195-200.
3. Mostofi FK, Murphy GP, Mettlin C, Sesterhenn IA, Batsakis SU, Khaliq SU, et al. Pathology review in an early detection program: results from the American Cancer Society-National Prostate Cancer Detection Project. Prostate 1995;27:7-12.
4. Mettlin C, Murphy GP, Lee F, Littrup P, Chesley A, Babaian R, et al. Characteristics of prostate cancers detected in a multimodality early detection program. Cancer 1993;72:1701-8.
5. Mettlin C, Murphy GP, Lee F, Littrup PJ, Chesley A, Babaian R, et al. Characteristics of prostate cancer detected in the American Cancer Society-National Prostate Cancer Detection Project. J Urol 1994;152:1737-40.
6. Mettlin C, Murphy GP, McGuinnis LS, Menck HR. The national cancer data base. Report on prostate cancer. Cancer 1995;76:1104-12.
7. Kane RA, Littrup PJ, Babaian R, Drago JR, Lee F, Chesley A, et al. PSA levels in 1,695 men without evidence of prostate cancer: findings from the American Cancer Society-NPCDP. Cancer 1992;69:1201-7.
8. Mettlin C, Murphy GP, Babaian RJ, Chesley A, Kane RA, Littrup PJ, et al. The results of a five-year early prostate cancer detection intervention. Cancer 1996;77:150-9.
9. Littrup PJ, Kane RA, Mettlin CJ, Murphy GP, Lee F, Toi A, et al. Cost-effective prostate cancer detection: reduction of low-yield biopsies. Cancer 1994;74:3146-58.
10. Murphy GP, Hutter R. Introduction to the American Cancer Society workshop on PSA: benefits and limitations. Cancer 1993;71:2677-83.
11. Murphy GP. Markers of prostatic carcinoma. Arch Surg 1991;126:1404-7.
12. Murphy GP. The second Stanford conference on international standardization of PSA assays. Cancer 1995;75:1-7.
13. Catalona WJ, Smith DS, Wolfert RL, Wang TJ, Rittenhouse HG, Ratliff TL, et al. Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. JAMA 1995;274:1214-20.
14. Lilja H, Christensson A, Dahlen U, Matikinen MT, Nilsson O, Pettersson K, et al. Prostate specific antigen in serum occurs predominately in complex with Alpha-1-antichymotrypsin. Clin Chem 1991;37:1618-25.
15. Stenman U-H, Leinaon J, Alfthan H, Rannikko S, Tuhkaren K, Alfthan O. A complex between prostate-specific antigen and Alpha-1-Antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostate cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res 1991;51:222-6,
16. Rochon YP, Horoszewicz JS, Boynton AL, Holmes EH, Barren RJ III, Reckon SJ, et al. Western blot assay for prostate-specific membrane antigen in serum of prostate cancer patients. Prostate 1994;25:219-23.
17. Murphy GP, Holmes EH, Boynton AL, Kenny GM, Ostenson RC, Erickson SJ, et al. A comparison of prostate specific antigen, prostate specific membrane antigen, and LNCaP based ELISA assays in prostatic cancer patients and patients with benign prostatic enlargement. Prostate 1995;26:164-8.
18. Horoszewicz JS, Kawinski E, Murphy GP. Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients. Anticancer Res 1987;7:927-36.
19. Murphy G, Ragde H, Kenny G, Barren R III, Erickson S, Tjoa B, et al. Comparison of prostate specific membrane antigen, and prostate specific antigen levels in prostatic cancer patients. Anticancer Res 1995;15:1473-80.
20. 111In-labeled monoclonal antibody 7E11.C5.3 (CYT-356). Prostate 1991;18:229-41.
21. Ohori M, Wheeler TM, Scardino P. The New American Joint Committee on Cancer and International Union Against Cancer TNM classification of prostate' cancer. Cancer 1994;74:104-13.
22. Schöder FH, Hermanek P, Denis L, Fair WR, Gospodarowicz MK, Pavone-Macaluso M. The TNM classification of prostate cancer. Prostate 1994;(Suppl 4):129-38.
23. Mostofi FK, Sesterhenn IA, Sobin LH. International histological classification of prostatic tumors. Geneva: World Health Organization, 1977.
24. Gleason DF and the Veterans Administration Cooperative Urological Research Group. Histological grading and clinical staging of prostatic carcinoma. In: Tannenbaum M, editor. Urologic pathology: the prostate. Philadelphia: Lea & Febiger, 1987:171-87.
25. Villers A, McNeal JE, Freiha FS, Stamey TA. Multiple cancers in the prostate. Morphologic features of clinically recognized versus incidental tumors. Cancer 1992;70:2313-8.
26. Metz CE: Basic principles of ROC analysis. Semin Nucl Med 1978;8:283-98.
27. Morton RA, Steiner MS, Walsh PC. Cancer control following anatomical radical prostatectomy: an interim report. J Urol 1991;145:1197-200.
28. Partin AW, Yoo J, Carter HB, Pearson JD, Chan DW, Epstein JI, et al. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol 1993;150:110-4.
29. Murphy GP. Radioscintiscanning of prostate cancer. Cancer 1995;78(Suppl):1819-22.